Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Introduction to the 2024 Consensus Guidelines for the Management of Neutropenic Fever in Patients with Cancer: Principles & Practice of Neutropenic Fever.
Thursky KA, Singh N, Slavin MA, Weinkove R, Haeusler GM, Hickman J, Jessop S, Lambros B, Routledge D, Sasadeusz J, Roberts JA, Mileshkin LR, Conyers R, Douglas AP; Australasian Neutropenic Fever Guidelines Steering Committee. Thursky KA, et al. Among authors: mileshkin lr. Intern Med J. 2025 Dec;55 Suppl 7:9-19. doi: 10.1111/imj.70237. Intern Med J. 2025. PMID: 41521413 Review.
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.
Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Leary A, Ottevanger PB, McCormack M, Khaw P, D'Amico R, Fyles A, Chargari C, Kitchener HC, Do V, Lissoni A, Provencher D, Genestie C, Nijman HW, Whitmarsh K, Jürgenliemk-Schulz IM, Feeney A, Lutgens LCHW, Bouma J, Leon-Castillo A, Nout RA, Putter H, Bosse T, Creutzberg CL. Post CCB, et al. Among authors: mileshkin l. Lancet Oncol. 2025 Oct;26(10):1370-1381. doi: 10.1016/S1470-2045(25)00379-1. Epub 2025 Sep 5. Lancet Oncol. 2025. PMID: 40921169 Free PMC article. Clinical Trial.
Cancer of the corpus uteri: A 2025 update.
Koskas M, Crosbie EJ, Fokdal L, McCluggage WG, Mileshkin L, Mutch DG, Amant F. Koskas M, et al. Among authors: mileshkin l. Int J Gynaecol Obstet. 2025 Sep;171 Suppl 1(Suppl 1):60-77. doi: 10.1002/ijgo.70326. Epub 2025 Jul 7. Int J Gynaecol Obstet. 2025. PMID: 40622006 Free PMC article. Review.
Erratum to 'Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101644].
Obermair A, Gebski V, Goh J, Kuchel A, Brand A, Mak B, McNally O, Baxter E, Jobling T, Mileshkin L. Obermair A, et al. Among authors: mileshkin l. Int J Gynecol Cancer. 2025 Sep;35(9):101961. doi: 10.1016/j.ijgc.2025.101961. Epub 2025 Jun 11. Int J Gynecol Cancer. 2025. PMID: 40506308 No abstract available.
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balázs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagaméri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Olawaiye AB, et al. Among authors: mileshkin l. Lancet. 2025 Jun 21;405(10496):2205-2216. doi: 10.1016/S0140-6736(25)01040-2. Epub 2025 Jun 2. Lancet. 2025. PMID: 40473448 Clinical Trial.
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary.
Rebello RJ, Posner A, Dong R, Prall OWJ, Sivakumaran T, Mitchell CB, Flynn A, Caneborg A, Mitchell C, Kanwal S, Fedele C, Webb S, Fisher K, Wong HL, Balachander S, Zhu W, Nicolson S, Dimitriadis V, Wilcken N, DeFazio A, Gao B, Singh M, Collins IM, Steer C, Warren M, Karanth N, Xu H, Fellowes A, Hicks RJ, Stewart KP, Shale C, Priestley P, Dawson SJ, Vissers JHA, Fox SB, Schofield P, Bowtell D, Hofmann O, Grimmond SM, Mileshkin L, Tothill RW. Rebello RJ, et al. Among authors: mileshkin l. Nat Commun. 2025 May 20;16(1):4422. doi: 10.1038/s41467-025-59661-x. Nat Commun. 2025. PMID: 40393956 Free PMC article.
Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma.
Obermair A, Gebski V, Goh J, Kuchel A, Brand A, Mak B, McNally O, Baxter E, Jobling T, Mileshkin L. Obermair A, et al. Among authors: mileshkin l. Int J Gynecol Cancer. 2025 Apr;35(4):101644. doi: 10.1016/j.ijgc.2025.101644. Epub 2025 Jan 16. Int J Gynecol Cancer. 2025. PMID: 39955187
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin.
Ugalde A, Tothill RW, Quinn S, Wong HL, Prall O, Mitchell C, Wickramasinghe N, Fedele C, Richards N, Todio E, Bryant C, Collins LG, McLean S, Ko HS, Akhurst T, Steer C, Gao B, Wong M, Georgiou C, Karanth N, Kuchel A, Nott L, Padinharakam S, Shackleton M, Collins IM, Singh M, Wong R, Wong ZW, Butler A, Sivakumaran T, Schofield P, Mileshkin L. Ugalde A, et al. Among authors: mileshkin l. BMC Cancer. 2025 Jan 29;25(1):171. doi: 10.1186/s12885-025-13506-4. BMC Cancer. 2025. PMID: 39881222 Free PMC article.
305 results